Clinical features and prognosis of 376 patients with T1micN 0M0, T1aN0M0 and T 1bN0M0 breast cancer
10.3781/j.issn.1000-7431.2011.11.012
- Author:
Jun-Nan LI
1
Author Information
1. Department of Breast Oncology
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Prognosis;
T 1aN0M0;
T1bN0M 0;
T1micN0M0
- From:
Tumor
2011;31(11):1026-1030
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinicopathological features and prognosis of patients with T1micN0M0, T1aN 0M0 and T1bN0M0 breast cancer, and to evaluate the survival and independent prognostic factors. Methods: The clinicopathological data from 4 487 patients who could receive surgical operation between January 2002 and December 2005 were collected. The clinicopathological features, recurrence, metastasis and survival of 376 patients with T1micN0M0, T1aN 0M0 and T1bN0M0 breast cancer were retrospectively analyzed. Results: Three hundred and seventy-six eligible patients were identified. Of these 376 patients, 66 patients (17.6%) had T1mic breast cancer (pT≤0.1 cm), 122 patients (32.4%) had T1mic breast cancer (0.1 cm < pT≤0.5 cm), and 188 patients (50.0%) had T1b breast cancer (0.5 cm < pT≤1.0 cm). With the lager tumor size, the histology grade was higher, the positive rate of estrogen receptor was lower, and the incidence of adjuvant chemotherapy was higher (P < 0.05). Univariate analysis showed that the age, hormone receptor and HER-2 status were prognostic factors for 5-year disease-free survival. Multivariate analysis showed that the hormone receptor and HER-2 were prognostic factors for 5-year disease-free survival. The 5-year recurrence risk in the positive hormone receptor group was four times as high as that in the negative hormone receptor group (hazard ratio was 4.995, 95% confidence interval was 1.113-22.424). In negative hormone receptor group, there was no statistically significant difference in the risk of 5-year recurrence between patients with positive HER-2 and negative HER-2 (hazard ratio was 2.757, 95% confidence interval was 0.849-8.955). Conclusion: HR and HER-2 status were independent prognostic factors for 5-year DFS in T1micN0M0, T 1aN0M0 and T1bN0M 0 breast cancer. Hormone receptor positive disease with positive HER-2 status was associated with a high risk of cancer recurrence. Copyright© 2011 by TUMOR.
